Viral hepatitis is a communicable disease that can cause serious liver damage and liver cancer. Deaths from viral hepatitis, the majority (96%) are due to hepatitis B and C, are rising worldwide compared to the downward trend for the other three most common causes of communicable diseases. However, hepatitis is preventable, treatable, and for Hepatitis C, curable with timely treatment.
These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect.